Fibroblast growth factor-23 concentrations in polycystic ovary syndrome

FGF23 concentrations did notcorrelate with BMI, fasting glucose and insulin, HOMA-IRand lipid parameters.Conclusions: FGF23 concentrations were similar in thePCOS group compared with the non-PCOS control group.The present findings may suggest that FGF23 is not a usefulmarker of metabolic disturbances including insulinresistance, dyslipidemia, and obesity in PCOS.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: This study was designed to compare the serumconcentrations of Fibroblast growth factor 23 (FGF23)among patients with PCOS and healthy subjects and toevaluate the relation between the hormonal and metabolicparameters.Methods: Forty patients with PCOS were compared with40 healthy individuals in a case-control study design.

📊

Key Findings & Data:TheRotterdam ESHRE/ASRM-sponsored PCOS ConsensusWorkshop Group 2003 guideline criteria were used in thediagnosis of PCOS.

💡

Conclusion & Impact:FGF23 concentrations did notcorrelate with BMI, fasting glucose and insulin, HOMA-IRand lipid parameters.Conclusions: FGF23 concentrations were similar in thePCOS group compared with the non-PCOS control group.The present findings may suggest that FGF23 is not a usefulmarker of metabolic disturbances including insulinresistance, dyslipidemia, and obesity in PCOS.

🔬Design:Research Article

📍Scope:2003 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: This study was designed to compare the serumconcentrations of Fibroblast growth factor 23 (FGF23)among patients with PCOS and healthy subjects and toevaluate the relation between the hormonal and metabolicparameters.Methods: Forty patients with PCOS were compared with40 healthy individuals in a case-control study design. TheRotterdam ESHRE/ASRM-sponsored PCOS ConsensusWorkshop Group 2003 guideline criteria were used in thediagnosis of PCOS. Serum intact FGF23 concentrationswere determined by enzyme-linked immunosorbent assay(ELISA).Results: Mean serum FGF23 concentrations were similarbetween PCOS group and control group (19.73 ± 16.75 pg/mL and 17.20 ± 9.26 pg/mL, p > 0.05). Waist circumference,hip circumference, total testosterone, Ferriman-Gallwey(FG) score and hsCRP were significantly higher in the PCOSgroup (p < 0.001). The concentrations of LH, DHEA-S, FSH,insulin, total cholesterol, triglyceride, HOMA-IR weresignificantly higher in the PCOS group when comparedto control group (p < 0.05). FGF23 concentrations did notcorrelate with BMI, fasting glucose and insulin, HOMA-IRand lipid parameters.Conclusions: FGF23 concentrations were similar in thePCOS group compared with the non-PCOS control group.The present findings may suggest that FGF23 is not a usefulmarker of metabolic disturbances including insulinresistance, dyslipidemia, and obesity in PCOS.

Özet

Amaç: PCOS’lu hastalarda FGF23 düzeylerini sağlıklı bireylerdeki ile karşılaştırmak ve FGF23 düzeylerinin hormonal ve metabolik parametreler ile ilişkisini değerlendirmekti. Yöntem: Bu vaka-kontrol çalışmasına PCOS’u olan 40 hasta ile sağlıklı 40 kadın alındı. Gruplar demografik, antropometrik ve biyokimyasal veriler ile serum FGF23 düzeylerine göre karşılaştırıldı. Serum FGF23 düzeyleri ELISA yöntemi ile insan FGF23 ELISA kiti kullanılarak ölçüldü. Bulgular: Ortalama serum FGF-23 düzeyleri PCOS grubunda ve kontrol grubunda benzerdi (19.73 ± 16.75 pg/mL ve 17.20 ± 9.26 pg/mL, p > 0.05). PCOS grubunda vücut kitle indeksi (VKİ), bel çevresi, kalça çevresi, Ferriman– Gallwey skoru, total testosteron ve hsCRP düzeyleri kontrol grubuna göre yüksek bulundu (p < 0.001). PCOS grubunda LH, DHEA-S, FSH, insülin, total kolesterol, trigliserid düzeyleri ve HOMA-IR kontrol grubuna göre yüksek bulundu (p < 0.05). FGF23 düzeyleri ile VKİ, açlık glukoz düzeyleri, insülin düzeyleri, HOMA-IR ve lipid parameterleri arasında ilişki saptanmadı.Sonuç: Serum FGF-23 düzeyleri her iki grupta benzerdi. Bu çalışmadan elde edilen bulgular, FGF23’ün PCOS’lu hastalarda insülin direnci, dislipidemi ve obezite gibi metabolik parametreler için kullanışlı bir serum belirteci olamayacağını düşündürmektedir.

🔖

Cite This Article

ÇAKAL, E., ÇELİK, B., ÇULHA, C., DEMİRCİ, T., KAN, S., KIZILGÜL, M., ARSLAN, M. S., APAYDIN, M., ÇALIŞKAN, M. (2022). Fibroblast growth factor-23 concentrations in polycystic ovary syndrome. Türk Biyokimya Dergisi, Cilt: 43 - Sayı: 1, 83–88. https://ajindex.com/articles/620941

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219–31
Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012;11:2937–46
Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med 2012;10:153
Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome. Nat Rev Endocrinol 2014;10: 624–36
Diamanti-Kandarakis E, Dunaif A. Insulin resistance, and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012;33:981–1030
Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812–41
Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the Klothodependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007;27:3417–28
Yamashita T. Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 2005;9:313–18. 9. Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:160–66
Krupp K, Madhivanan P. FGF23 and risk of all-cause mortality and cardiovascular events: a meta-analysis of prospective cohort studies. Int J Cardiol 2014;176:1341–42
Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 2012;97:1655–62
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva: World Health Organization, 2000
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell fun